Albireo Pharma Inc., of Boston, said Japan's Ministry of Health, Labor and Welfare approved the new drug application for IBAT inhibitor elobixibat for the treatment of chronic constipation, triggering payments from Eisai Co. Ltd. subsidiary EA Pharma Co. Ltd., of Tokyo, under a license agreement and from Healthcare Royalty Partners under the terms of a royalty monetization agreement disclosed earlier this year, which together total more than $55 million.